HomeMarkets Markets In first test for base editing, Verve’s one-time treatment lowers cholesterol levels in patients By news November 12, 2023 0 315 FacebookTwitterPinterestWhatsApp Verve Therapeutics said Sunday that the first 10 people to receive a one-time treatment powered by a form of CRISPR called base editing showed …This post was originally published on this site Share FacebookTwitterPinterestWhatsApp Subscribe Login Notify of new follow-up comments new replies to my comments Please login to comment 0 Comments Inline Feedbacks View all comments Stay Connected149,466FansLike396,312FollowersFollow2,650SubscribersSubscribe Latest Articles Markets The Death of Khamenei and the End of an Era Markets Trump Says Iran’s Supreme Leader Is Dead Market News US‑Israeli attack on Iran risks plunging the world into turmoil (and my take) Markets ☢️ World War Trump: The Pentagon Ultimatum – AI Weaponization and Constitutional Collapse Hot Items Zeihan: Attack on Iran Underway AI Anthropic CEO responds to Trump order, Pentagon clash Charts PSW’s Weekly Webinar: The State of the Markets Report (2/25/2026) AI Trump Orders Government to Stop Using Anthropic After Pentagon Standoff Markets Fall Back Friday – February Ending on a Week Note? AI AI “hot takes” are becoming a market risk Hot Items How Trump’s renewed tariff chaos will stifle investment around the world Market News Netflix Backs Out of Bid for Warner Bros., Paving Way for an Ellison Takeover AI Anthropic Takes a Stand Markets A Modest Proposal For Solving the AI Energy Crisis Load more